Professor Gabriella gobbi and his team from Universite de Montreal have found that the new drug URB597 increases the level of endocannabinoids by blocking the degradation in the brain and relaxes depression. Endocannabinoids are chemicals present in brain which is responsible for relaxing brain, endocannabinoids are released when specific brain receptors are triggered during exercises and other well-being activities. The level of endocannabinoids is measured by measuring the levels of serotonin and noradrenalin. Researchers have published the results of their work in the Journal Proceedings of the National Academy of Sciences (PNAS).
Professor Gobbi said, 'This is the first time it has been shown that a drug that increases endocannabinoids in the brain can improve your mood, our discovery strengthens the case for URB597 as a safer, non-addictive, non-psychotropic alternative to cannabis for the treatment of pain and depression and provides hope for the development of an alternate line of antidepressants, with a wider range of effectiveness'.